Annex 26

to the Procedure for Conducting Expert Evaluation of Registration Materials Pertinent to Medicinal Products Submitted for the State Registration (Re-Registration) and for Expert Evaluation of Materials about Introduction of Changes to Registration Materials during the Validity Period of Registration Certificate (item 4 of section VI)

REGISTRATION FORM
for changes to registration materials pertinent to medicinal product

Submitted on ____, _____ 20____	№ _____

I hereby declare that:

□ There are no other changes than those identified in this registration form (except for those addressed in other registration forms submitted in parallel);

□ All conditions (as per Annex 17 to the Procedure) for the change(s) are fulfilled, if applicable;

□ The required documents (as per annex 17 to the Procedure) for the change(s) have been submitted.

Changes will be implemented (tick where appropriate):*

□ From the next manufacturing run/next printing,

□ Date _____

* Only for Type IB and II variations, and the administrative changes (Type IA) at their introduction to the instructions for medical use and labelling text on package of the finished medicinal products.

All fees will be been paid in accordance with the requirements of the current legislation.

I guarantee the reliability of information contained in the registration materials submitted and bear responsibility for this foreseen by the current legislation.

I agree that in case of non-submission of materials of the registration dossier within 3 months after receipt of a MoH's letter of referral by the Center, an application for introduction of changes relating to this medicinal product will be annulled.

Main signature _____ _____ (full name)	_____ (position) «____»_____20_____
Second signature _____ (if applicable) _____ (full name)	_____ (position) «____»_____20_____

Type of variations (tick appropriate)

- ☐ Type IA_{IN}
- ☐ Type IA
- ☐ Type IB
- ☐ Type II

- ☐ safety
- ☐ urgent safety restriction
- ☐ quality
- ☐ other

Name of medicinal product	
Active substance(s)	
Pharmaceutical form, dose	
Type, size and contents of package	
Registration certificate number (s)	
Applicant	
Person authorized to act on behalf of applicant	

Notes:

In case of Type II variations, the list of Type I variations given below shall be deleted.

In case of Type IA variations, those Type I variations, not included in the registration form, shall be deleted.

Please select the applicable variation(s) from the list presented below and include in the section "Type of variation". To apply for variations not foreseen in this classification, the applicant should declare such other variation ("x") in the appropriate section.

A. ADMINISTRATIVE CHANGES	**Type of variation**
□ x) other variations	□ IA □ IB □ II

	Type of variation	
□ **A.1. Change in the name and/or address of the applicant (registration certificate holder)**	□ IA_{IN}	□ IB*

* If one of the conditions is not met and the change is not listed as Type II.

	Type of variation
□ **A.2. Change in the name of the medicinal product**	IB

	Type of variation	
□ **A.3. Change in name of the API or of an excipient**	□ IA_{IN}	□ IB*

* If one of the conditions is not met and the change is not listed as Type II.

	Type of variation	
□ **A.4. Change in the name and/or address where a manufacturer carries out his activity (including where relevant quality control testing sites); or an holder of API master file; or a supplier of the API/starting material/reagent/intermediate used in the manufacture of the API (where specified in the dossier for the medicinal product) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the dossier)**	□ IA	□ IB*

* If one of the conditions is not met and the change is not listed as Type II.

A.5. Change in the name and/or address where a manufacturer carries out his activity /importer of the finished medicinal product (including batch release or quality control testing sites)	**Type of variation**	
□ a) The activities for which the manufacturer/importer is responsible include batch release	□ IA_{IN}	□ IB*
□ b) The activities for which the manufacturer/importer is responsible do not include batch release	□ IA	□ IB*

* If one of the conditions is not met and the change is not listed as Type II.

	Type of variation	
□ **A.6. Change in ATC Code**	□ IA	□ IB*

* If one of the conditions is not met and the change is not listed as Type II.

	Type of variation	
□ **A.7. Deletion of any manufacturing site (including sites for an API, intermediate or finished medicinal product, packaging site, manufacturer responsible for batch release, site where batch control takes place) or supplier of a starting material, reagent or excipient (when mentioned in the dossier)**	□ IA	□ IB*

* If one of the conditions is not met and the change is not listed as Type II.

	Type of variation
□ **A.8. Changes to date of the audit to verify good manufacturing practice (GMP) compliance of the manufacturer of the API***	□ IA

B. QUALITY CHANGES	
B.I. API	
B.I.a) Manufacture	**Type of variation**
□ x) other variations	□ IA □ IB □ II

B.I.a.1. Change in the manufacturer of a starting material/ intermediate/reagent used in the manufacturing process of the API or change in the manufacturer (including where relevant quality control testing site(s)) of the API, where no Ph. Eur. Certificate of Suitability is part of the approved	**Type of variation**

dossier		
□ a) The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer.	□ IA_{IN}	□ IB*
□ b) Introduction of a new manufacturer of the API supported by an API master file.	II	
□ c) The proposed manufacturer uses a substantially different route of synthesis or manufacturing conditions, which may have a potential to change important quality characteristics of the API, such as qualitative and/or quantitative impurity profile requiring qualification, or physico-chemical properties of API impacting on bioavailability	II	
□ d) New manufacturer of a starting material for which an assessment is required of viral safety and/or TSE risk	II	
□ e) The change relates to a biological API or a starting material/reagent/intermediate used in the manufacture of a biological/immunological product	II	
□ f) Changes to quality control testing arrangements for the API - replacement or addition of a site where batch control/testing takes place	□ IA	□ IB*
□ g) Introduction of a new manufacturer of the API that is not supported by an APIMF and requires significant update to the relevant API section of the dossier	II	
□ h) Addition of an alternative sterilisation site for the API using a Ph.Eur. method	IB	
□ i) Introduction of a new site of micronisation	□ IA	□ IB*
□ j) Changes to quality control testing arrangements for a biological active substance: replacement or addition of a site where batch control/testing including a biological/immunological/immunochemical method takes place	II	
□ k) New storage site of Master Cell Bank and/or Working Cell Banks	IB	
□ x) other variations	□ IA □ IB □ II	

* If one of the conditions is not met and the change is not listed as Type II.

B.I.a.2. Changes in the manufacturing process of the API	**Type of variation**

□ a) Minor change in the manufacturing process of the API	□ IA	□ IB*
□ b) Substantial change to the manufacturing process of the API which may have a significant impact on the quality, safety or efficacy of the medicinal product.	II	
□ c) The change refers to a biological/immunological active substance or use of a chemically derived API in the manufacture of a biological/immunological substance, which may have a significant impact on the quality, safety and efficacy of the medicinal product and is not related to a protocol	II	
□ d) The change relates to a herbal medicinal product and there is a change to any of the following: geographical source, manufacturing route or production	II	
□ e) Minor change to the restricted part of an API Master File	IB	
□ x) other variations	□ IA □ IB □ II	

* If one of the conditions is not met and the change is not listed as Type II.

B.I.a.3. Change in batch size (including ranges) of API or intermediate used in the manufacturing process of the API	**Type of variation**	
□ a) Up to 10-fold increase compared to the approved batch size	□ IA	□ IB*
□ b) Downscaling down to 10-fold	□ IA	□ IB*
□ c) The change requires assessment of the comparability of a biological/immunological active substance	II	
□ d) More than 10-fold increase compared to the approved batch size	IB	
□ e) The scale for a biological/immunological active substance is increased/decreased without process change (e.g. duplication of line)	IB	
□ x) other variations	□ IA □ IB □ II	

* If one of the conditions is not met and the change is not listed as Type II.

B.I.a.4. Change to specification in-process tests or limits applied during the manufacture of the API	**Type of variation**	
□ a) Tightening of limits	□ IA	□ IB*
□ b) Addition of a new test and limits	□ IA	□ IB*
□ c) Deletion of a non-significant test	□ IA	□ IB*
□ d) Widening of the approved in-process test limits, which may have a significant effect on the overall quality of the API	II	

□ e) Deletion of an in-process test which may have a significant effect on the overall quality of the API	II
□ f) Addition or replacement of an test as a result of a safety or quality studies	IB
□ x) other variations	□ IA □ IB □ II

* If one of the conditions is not met and the change is not listed as Type II.

B.I.a.5. Changes to the active substance of a seasonal, pre-pandemic or pandemic vaccine against human influenza	**Type of variation**
□ a) Replacement of the strain(s) in a seasonal, pre-pandemic or a pandemic vaccine against human influenza	II

B.1.b) Control of the API	**Type of variation**
□ x) other variations	□ IA □ IB □ II

B.I.b.1. Change in the specification parameters and/or limits of an API, or starting material/intermediate/reagent used in the manufacturing process of the API	**Type of variation**	
□ a) Tightening of specification limits for medicinal products subject to Official Regulatory Authority Batch Release	□ IA_{IN}	□ IB*
□ b) Tightening of specification limits	□ IA	□ IB*
□ c) Addition of a new specification quality parameter to the specification with its corresponding test method	□ IA	□ IB*
□ d) Deletion of a non-significant specification parameter (e.g. an obsolete parameter)	□ IA	□ IB*
□ e) Deletion of a specification parameter which may have a significant effect on the quality of the API and/or the finished medicinal product	II	
□ f) Change outside the approved specifications limits range for the API	II	
□ g) Widening of the approved specifications limits for starting materials/intermediates, which may have a significant effect on the quality of the API and/or the finished product	II	
□ h) Addition or replacement (excluding biological or immunological active substance) of a specification parameter with its corresponding test method as a result of a safety or quality studies	IB	
□ i) Where there is no monograph in the SPhU or the European Pharmacopoeia or national pharmacopoeia of an EU state for the API, a change in specification from in-house to a non-official	IB	

Pharmacopoeia or a Pharmacopoeia of a third country	
□ x) other variations	□ IA □ IB □ II

* If one of the conditions is not met and the change is not listed as Type II.

B.I.b.2. Change in test procedure for API or starting material/ intermediate/reagent used in the manufacturing process of the API	**Type of variation**	
□ a) Minor changes to an approved test procedure	□ IA	□ IB*
□ b) Deletion of a test procedure for the API or a starting material/reagent/intermediate, if an alternative test procedure is already authorised	□ IA	□ IB*
□ c) Other changes to a test procedure (including replacement or addition) for a reagent, which does not have a significant effect on the quality of the API	□ IA	□ IB*
□ d) Substantial change to or replacement of a biological/ immunological/ immunochemical test method or a method using a biological reagent for a biological API	II	
□ e) Other changes to a test procedure (including replacement or addition) for the API or a starting material/intermediate	IB	

* If one of the conditions is not met and the change is not listed as Type II.

B.I.c) Container closure system	**Type of variation**
□ x) other variations	□ IA □ IB □ II

B.I.c.1. Change in immediate packaging of the API	**Type of variation**	
□ a) Changes to qualitative and/or quantitative composition	□ IA	□ IB*
□ b) Changes to qualitative and/or quantitative composition for sterile and non-frozen biological/immunological API	II	
□ c) Liquid API (non sterile)	IB	
□ x) other variations	□ IA □ IB □ II	

* If one of the conditions is not met and the change is not listed as Type II.

B.I.c.2. Change in the specification parameters and/or limits of the immediate packaging of the API	**Type of variation**

□ a) Tightening of specification limits	□ IA	□ IB*
□ b) Addition of a new specification parameter to the specification with its corresponding test method	□ IA	□ IB*
□ c) Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)	□ IA	□ IB*
□ d) Addition or replacement of a specification parameter as a result of a safety or quality study	IB	
□ x) other variations	□ IA □ IB □ II	

* If one of the conditions is not met and the change is not listed as Type II.

B.I.c.3. Change in test procedure for the immediate packaging of the API	**Type of variation**	
□ a) Minor changes to an approved test procedure	□ IA	□ IB*
□ b) Other changes to a test procedure (including replacement or addition)	□ IA	□ IB*
□ c) Deletion of a test procedure if an alternative test procedure is already authorised	□ IA	□ IB*

* If one of the conditions is not met and the change is not listed as Type II.

B.I.d) Stability		
B.I.d.1. Change in the re-test period/storage period or storage conditions of the API (where no Ph. Eur. Certificate of Suitability covering the retest period is part of the approved dossier)	**Type of variation**	
a) Re-test period/storage period		
□ 1. Reduction	□ IA	□ IB*
□ 2. Extension of the retest period based on extrapolation of stability data not in accordance with EMA guidelines on stability testing or MoH Ukraine documents 42-3.3:2004 and 42-8.2:2013	II	
□ 3. Extension of storage period of a biological/ immunological active substance supported by results of the studies conducted not in accordance with an approved stability protocol	II	
□ 4. Extension or introduction of a re-test period/storage period supported by results of real time study	IB	
b) Storage conditions		
□ 1. More restrictive storage conditions	□ IA	□ IB*

□ 2. Change in storage conditions of biological/immunological active substances, when the stability studies have not been performed in accordance with an approved protocol	II	
□ 3. Change in storage conditions of the API	IB	
□ c) Change to an approved stability protocol	□ IA	□ IB*
□ x) other variations	□ IA □ IB □ II	

* If one of the conditions is not met and the change is not listed as Type II.

B.I.e) Design space and postregistration change management protocol	
B.I.e.1. Introduction of a new design space or extension of an approved design space for the API, concerning:	**Type of variation**
□ a) One unit operation in the manufacturing process of the API including the in-process controls and/or test procedures	II
□ b) Test procedures for starting materials/reagents/ intermediates and/or the API	II

	Type of variation
□ **B.I.e.2. Introduction of a postregistration change management protocol related to the API**	II

	Type of variation	
□ **B.I.e.3. Deletion of an approved change management protocol related to the API**	□ IA_{IN}	□ IB*

* If one of the conditions is not met and the change is not listed as Type II.

B.I.e.4. Changes to an approved change management protocol	**Type of variation**
□ a) Major changes to an approved change management protocol	II
□ b) Minor changes to an approved change management protocol that do not change the strategy defined in the protocol	IB
□ x) other variations	□ IA □ IB □ II

B.I.e.5. Implementation of changes foreseen in an approved	**Type of**

change management protocol	variation	
□ a) The implementation of the change requires no further supportive data	□ IA_{IN}	□ IB*
□ b) The implementation of the change requires further supportive data	IB	
□ c) Implementation of a change for a biological/immunological medicinal product	IB	
□ x) other variations	□ IA □ IB □ II	

* If one of the conditions is not met and the change is not listed as Type II.

B.II. FINISHED MEDICINAL PRODUCT	
B.II.a) Description and composition	**Type of variation**
□ x) other variations	□ IA □ IB □ II

B.II.a.1. Change or addition of imprints, bossing or other markings including replacement, or addition of inks used for medicinal product marking	**Type of variation**	
□ a) Changes in imprints, bossing or other markings	□ IA_{IN}	□ IB*
□ b) Changes in scoring/break lines intended to divide tablets into equal doses	IB	
□ x) other variations	□ IA □ IB □ II	

* If one of the conditions is not met and the change is not listed as Type II.

B.II.a.2. Change in the shape or dimensions of the pharmaceutical form	**Type of variation**	
□ a) Immediate release tablets, capsules, suppositories and pessaries	□ IA_{IN}	□ IB*
□ b) Gastro-resistant, modified or prolonged release pharmaceutical forms and scored tablets intended to be divided into equal doses	IB	
□ c) Addition of a new kit for a radiopharmaceutical preparation with another fill volume	II	
□ x) other variations	□ IA □ IB □ II	

* If one of the conditions is not met and the change is not listed as Type II.

B.II.a.3. Changes in the composition (excipients) of the finished medicinal product	**Type of variation**
a) Flavouring or colouring system	

□ 1. Addition, deletion or replacement	□ IA_{IN}	□ IB*
□ 2. Increase or reduction	□ IA	□ IB*
b) Other excipients		
□ 1. Any minor change to the quantitative composition of the finished medicinal product with respect to excipients	□ IA	□ IB*
□ 2. Qualitative or quantitative changes in one or more excipients that may have a significant impact on the safety, quality or efficacy of the finished medicinal product	II	
□ 3. Change that relates to a biological/immunological medicinal product	II	
□ 4. Any new excipient that includes the use of materials of human or animal origin for which assessment is required of viral safety data or TSE risk	II	
□ 5. Change that is supported by a bioequivalence study	II	
□ 6. Replacement of a single excipient with a comparable excipient with the same functional characteristics and at a similar level	IB	
□ x) other variations	□ IA □ IB □ II	

* If one of the conditions is not met and the change is not listed as Type II.

B.II.a.4. Change in coating weight of oral dosage forms or change in weight of capsule shells	**Type of variation**	
□ a) Solid oral pharmaceutical forms	□ IA	□ IB*
□ b) Gastro-resistant, modified or prolonged release pharmaceutical forms where the coating is a critical factor for the release mechanism	II	
□ x) other variations	□ IA □ IB □ II	

* If one of the conditions is not met and the change is not listed as Type II.

	Type of variation
□ **B.II.a.5. Change in concentration of a single-dose, total use parenteral medicinal product, where the amount of API per unit dose (i.e. the strength) remains the same**	II

	Type of variation

□ **B.II.a.6. Deletion of the solvent/diluent container from the pack**	IB

B.II.b) Manufacture	**Type of variation**
□ x) other variations	□ IA □ IB □ II

B.II.b.1. Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished medicinal product	**Type of variation**	
□ a) Secondary packaging site	□ IA_{IN}	□ IB*
□ b) Primary packaging site	□ IA_{IN}	□ IB*
□ c) Site where any manufacturing operation(s) take place, except batch release, quality control, and secondary packaging, for biological/ immunological medicinal products or for pharmaceutical forms manufactured by complex manufacturing processes	II	
□ d) Site which requires an initial or product specific inspection	II	
□ e) Site where any manufacturing operation(s) take place, except batch-release, quality control, primary and secondary packaging, for non-sterile medicinal products	IB	
□ f) Site where any manufacturing operation(s) take place, except batch release, quality control, and secondary packaging, for sterile medicinal products (including those that are aseptically manufactured) excluding biological/ immunological medicinal products	IB	
□ x) other variations	□ IA □ IB □ II	

* If one of the conditions is not met and the change is not listed as Type II.

B.II.b.2. Change to importer/batch release arrangements and quality control testing of the finished medicinal product	**Type of variation**	
□ a) Replacement or addition of a site where batch control/testing takes place	□ IA	□ IB*
□ b) Replacement or addition of a site where batch control/testing takes place for a biological/immunological medicinal product and any of the test methods performed at the site is a biological/immunological method	II	
□ c) Replacement or addition of a manufacturer responsible for importation and/or batch release		

□ 1. Not including batch control/testing	□ IA_{IN}	□ IB*
□ 2. Including batch control/testing	□ IA_{IN}	□ IB*
□ 3. Including batch control/testing for a biological/immunological medicinal product and any of the test methods performed at that site is a biological/immunological/immunochemical method	II	
□ x) other variations	□ IA □ IB □ II	

* If one of the conditions is not met and the change is not listed as Type II.

B.II.b.3. Change in the manufacturing process of the finished medicinal product, including an intermediate used in the manufacture of the finished medicinal product	**Type of variation**	
□ a) Minor change in the manufacturing process	□ IA	□ IB*
□ b) Substantial change to a manufacturing process that may have a significant impact on the quality, safety and efficacy of the medicinal product	II	
□ c) The medicinal product is a biological/immunological medicinal product and the change requires a comparative study	II	
□ d) Introduction of a non-standard terminal sterilisation method	II	
□ e) Introduction or increase in the overage that is used for the API	II	
□ f) Minor change in the manufacturing process of an aqueous oral suspension	IB	
□ x) other variations	□ IA □ IB □ II	

* If one of the conditions is not met and the change is not listed as Type II.

B.II.b.4. Change in the batch size (including batch size ranges) of the finished medicinal product	**Type of variation**	
□ a) Up to 10-fold compared to the approved batch size	□ IA	□ IB*
□ b) Downscaling down to 10-fold	□ IA	□ IB*
□ c) The change requires assessment of the comparability (comparative studies) of a biological/immunological medicinal product or the change in batch size requires a new bioequivalence study	II	
□ d) The change relates to all other pharmaceutical forms manufactured by complex manufacturing processes	II	

□ e) More than 10-fold increase compared to the approved batch size for immediate release solid oral pharmaceutical forms	IB
□ f) The scale for a biological/immunological medicinal product is increased/decreased without process change (e.g. duplication of line)	IB
□ x) Other variations	□ IA □ IB □ II

* If one of the conditions is not met and the change is not listed as Type II.

B.II.b.5. Change to specification tests or limits applied during the manufacture of the finished medicinal product	**Type of variation**	
□ a) Tightening of limits	□ IA	□ IB*
□ b) Addition of a new test(s) and limits	□ IA	□ IB*
□ c) Deletion of a non-significant in-process test	□ IA	□ IB*
□ d) Deletion of an in-process test which may have a significant effect on the overall quality of the finished medicinal product	II	
□ e) Widening of the approved limits for parameters, which may have a significant effect on overall quality of the finished medicinal product	II	
□ f) Addition or replacement of an in-process test as a result of a safety or quality study	IB	
□ x) Other variations	□ IA □ IB □ II	

* If one of the conditions is not met and the change is not listed as Type II.

B.II.c) Control of excipients	**Type of variation**
□ x) other variations	□ IA □ IB □ II

B.II.c.1. Change in the specification parameters and/or limits of an excipient	**Type of variation**	
□ a) Tightening of limits	□ IA	□ IB*
□ b) Addition of a new parameter to the specification with its corresponding test method	□ IA	□ IB*
□ c) Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)	□ IA	□ IB*
□ d) Change outside the approved specifications limits range	II	

□ e) Deletion of a specification parameter which may have a significant effect on the overall quality of the finished medicinal product	II
□ f) Addition or replacement (excluding biological or immunological medicinal product) of a specification parameter with its corresponding test method, as a result of a safety or quality study	IB
□ g) Where there is no monograph in the SPhU, European Pharmacopoeia or national pharmacopoeia of an EU state for the excipient, a change in specification from in-house to a non-official Pharmacopoeia or a Pharmacopoeia of a third country	IB
□ x) other variations	□ IA □ IB □ II

* If one of the conditions is not met and the change is not listed as Type II.

B.II.c.2. Change in test procedure for an excipient	**Type of variation**	
□ a) Minor changes to the approved test procedures	□ IA	□ IB*
□ b) Deletion of a test procedure if an alternative test procedure is already authorised	□ IA	□ IB*
□ c) Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent	II	
□ d) Other changes to a test procedure (including replacement or addition)	IB	

* If one of the conditions is not met and the change is not listed as Type II.

B.II.c.3. Change in source of an excipient or reagent with TSE risk	**Type of variation**	
a) From TSE risk material to vegetable or synthetic origin		
□ 1. For excipients or reagents not used in the manufacture of a biological/immunological active substance or in a biological/immunological medicinal product	□ IA	□ IB*
□ 2. For excipients or reagents used in the manufacture of a biological/immunological active substance or in a biological/immunological medicinal product	IB	
□ b) Change or introduction of a TSE risk material or replacement of a TSE risk material from a different TSE risk material, not covered by a TSE certificate of suitability	II	

* If one of the conditions is not met and the change is not listed as Type II.

B.II.b.4. Change in synthesis or recovery of a non-pharmacopoeial excipient (when described in the dossier) or a novel excipient	**Type of variation**

□ a) Minor change in synthesis or recovery of a non-pharmacopoeial excipient or a novel excipient	□ IA	□ IB*
□ b) The specifications are affected or there is a change in physico-chemical properties of the excipient which may affect the quality of the finished medicinal product.	II	
□ c) The excipient is a biological/immunological substance	II	
□ x) Other variations	□ IA □ IB □ II	

* If one of the conditions is not met and the change is not listed as Type II.

B.II.d) Control of the finished medicinal product	**Type of variation**
□ x) Other variations	□ IA □ IB □ II

B.II.d.1. Change in the specification parameters and/or limits of the finished medicinal product	**Type of variation**	
□ a) Tightening of limits	□ IA	□ IB*
□ b) Tightening of specification limits for medicinal products subject to batch release approval by an official regulatory authority	□ IA_{IN}	□ IB*
□ c) Addition of a new parameter to the specification with its corresponding test method	□ IA	□ IB*
□ d) Deletion of a non-significant parameter (e.g. deletion of an obsolete parameter such as odour and taste or identification test for a colouring or flavouring material)	□ IA	□ IB*
□ e) Change outside the approved specifications limits range	II	
□ f) Deletion of a parameter which may have a significant effect on the quality of the finished medicinal product	II	
□ g) Addition or replacement (excluding biological or immunological medicinal product) of a specification parameter as a result of a safety or quality study	IB	
□ h) Update of the dossier to comply with the provisions of an updated general monograph of the SPhU/Ph. Eur for the finished dosage form	□ IA_{IN}	□ IB*
□ i) Changes to the dossier to comply with the introduced SPhU/Ph. Eur. General Chapter 2.9.40 Uniformity of dosage units to replace the approved, either Ph. Eur. 2.9.5 (Uniformity of mass). or Ph. Eur. 2.9.6 (Uniformity of content)	□ IA	□ IB*
□ x) Other variations	□ IA □ IB □ II	

* If one of the conditions is not met and the change is not listed as Type II.

B.II.d.2. Change in test procedure for the finished medicinal product	**Type of variation**	
□ a) Minor changes to an approved test procedure	□ IA	□ IB*
□ b) Deletion of a test procedure if an alternative method is already authorised	□ IA	□ IB*
□ c) Substantial change to, or replacement of a biological/ immunological/ immunochemical test method or a method using a biological reagent or replacement of a biological reference preparation not covered by an approved protocol	II	
□ d) Other changes to a test procedure (including replacement or addition)	IB	
□ e) Update of the test procedure to comply with the updated general monograph in the SPhU or Ph. Eur.	□ IA	□ IB*
□ f) To reflect compliance with the SPhU or Ph.Eur. and remove reference to the outdated internal test method and its number	□ IA	□ IB*

* If one of the conditions is not met and the change is not listed as Type II.

	Type of variation
□ **B.II.d.3. Variations related to the introduction of real-time release or parametric release in the manufacture of the finished medicinal product**	II

B.II.e) Container closure system	**Type of variation**
□ x) Other variations	□ IA □ IB □ II

B.II.e.1. Change in immediate packaging of the finished medicinal product	**Type of variation**	
a) Qualitative and quantitative composition		
□ 1. Solid pharmaceutical forms	□ IA	□ IB*
□ 2. Semi-solid and non-sterile liquid pharmaceutical forms	IB	
□ 3. Sterile medicinal products and biological/ immunological medicinal products	II	
□ 4. The change relates to a less protective pack where there are associated changes in storage conditions and/or reduction in shelf life	II	

b) Type of container or addition of a new container		
□ 1. Solid, semi-solid and non-sterile liquid pharmaceutical forms	IB	
□ 2. Sterile medicinal products and biological/ immunological medicinal products	II	
□ 3. Deletion of an immediate packaging container that does not lead to the complete deletion of a specific strength or specific pharmaceutical form of the medicinal product	□ IA	□ IB*
□ x) Other variations	□ IA □ IB □ II	

* If one of the conditions is not met and the change is not listed as Type II.

B.II.e.2. Change in the specification parameters and/or limits of the immediate packaging of the finished medicinal product	**Type of variation**	
□ a) Tightening of specification limits	□ IA	□ IB*
□ b) Addition of a new parameter to the specification with its corresponding test method	□ IA	□ IB*
□ c) Deletion of a non-significant parameter (e.g. deletion of an obsolete parameter)	□ IA	□ IB*
□ d) Addition or replacement of a parameter as a result of a safety or quality studies	IB	
□ x) Other variations	□ IA □ IB □ II	

* If one of the conditions is not met and the change is not listed as Type II.

B.II.e.3. Change in test procedure for the immediate packaging of the finished medicinal product	**Type of variation**	
□ a) Minor changes to an approved test procedure	□ IA	□ IB*
□ b) Other changes to a test procedure (including replacement or addition)	□ IA	□ IB*
□ c) Deletion of a test procedure if an alternative test procedure is already authorised	□ IA	□ IB*

* If one of the conditions is not met and the change is not listed as Type II.

B.II.e.4. Change in shape or dimensions of the container or closure (immediate packaging)	**Type of variation**	
□ a) Non-sterile medicinal products	□ IA	□ IB*
□ b) The change in shape or dimensions concerns a fundamental part of the packaging material, which may have a significant impact on the delivery, use, safety or stability of the finished medicinal product	II	
□ c) Sterile medicinal products	IB	

* If one of the conditions is not met and the change is not listed as Type II.

B.II.e.5. Change in pack size of the finished medicinal product	**Type of variation**	
a) Change in the number of units (e.g. tablets, ampoules, etc.) in a pack		
□ 1. Change within the range of the approved pack sizes	□ IA_{IN}	□ IB*
□ 2. Change outside the range of the approved pack sizes	IB	
□ b) Deletion of pack size(s)	□ IA	□ IB*
□ c) Change in the fill weight/fill volume of sterile multidose (or single-dose, partial use) parenteral medicinal products, including biological/immunological medicinal products.	II	
□ d) Change in the fill weight/fill volume of non-parenteral multidose (or single-dose, partial use) medicinal products	IB	
□ x) Other variations	□ IA □ IB □ II	

* If one of the conditions is not met and the change is not listed as Type II.

B.II.e.6. Change in any part of the primary packaging material not in contact with the finished medicinal product (such as colour of flip-off caps, colour code rings on ampoules, change of needle shield (different plastic used))	**Type of variation**	
□ a) Change that affects the summary of product characteristics	□ IA_{IN}	□ IB*
□ b) Change that does not affect the summary of product characteristics	□ IA	□ IB*

* If one of the conditions is not met and the change is not listed as Type II.

B.II.e.7. Change in supplier of packaging components or devices (when mentioned in the dossier)	**Type of variation**	
□ a) Deletion of a supplier	□ IA	□ IB*
□ b) Replacement or addition of a supplier	□ IA	□ IB*
□ c) Any change to suppliers of spacer devices for metered dose inhalers	II	

* If one of the conditions is not met and the change is not listed as Type II.

B.II.f) Stability		
B.II.f.1. Change in the shelf life or storage conditions of the finished medicinal product	**Type of variation**	
a) Reduction of the shelf life of the finished medicinal product		
□ 1. As packaged for sale	□ IA_{IN}	□ IB*

□ 2. After first opening	□ IA_{IN}	□ IB*
□ 3. After dilution or reconstitution	□ IA_{IN}	□ IB*
b) Extension of the shelf life of the finished medicinal product		
□ 1. As packaged for sale (supported by real time data)	IB	
□ 2. After first opening (supported by real time data)	IB	
□ 3. After dilution or reconstitution (supported by real time data)	IB	
□ 4. Extension of the shelf life based on extrapolation of stability data not in accordance with MoH Ukraine document 42-3.3:2004 or EMA guidelines on stability testing of medicinal products	II	
□ 5. Extension of the shelf-life of a biological/ immunological medicinal product based on results of the stability studies performed in accordance with an approved protocol.	IB	
□ c) Change in storage conditions for biological medicinal products, when the stability studies have not been performed in accordance with an approved protocol	II	
□ d) Change in storage conditions of the finished medicinal product or the diluted/reconstituted product	IB	
□ e) Change to an approved stability protocol	□ IA	□ IB*
□ x) Other variations	□ IA □ IB □ II	

* If one of the conditions is not met and the change is not listed as Type II.

B.II.g) Design space and postregistration change management protocol	
B.II.g.1. Introduction of a new design space or extension of an approved design space for the finished medicinal product (except for the biological medicinal products), concerning:	**Type of variation**
□ a) One or more unit operations in the manufacturing process of the finished medicinal product including the in-process controls and/or test procedures	II
□ b) Test procedures for excipients/intermediates and/or the finished medicinal product.	II

	Type of variation
□ **B.II.g.2. Introduction of a post approval change management protocol related to the finished medicinal product**	II

	Type of

	variation	
□ **B.II.g.3. Deletion of an approved change management protocol related to the finished medicinal product**	□ IA_{IN}	□ IB*

* If one of the conditions is not met and the change is not listed as Type II.

B.II.g.4. Changes to an approved change management protocol	**Type of variation**
□ a) Major changes to an approved change management protocol	II
□ b) Minor changes to an approved change management protocol that do not change the strategy defined in the protocol	IB
□ x) Other variations	□ IA □ IB □ II

B.II.g.5. Introduction of changes foreseen in an approved change management protocol	**Type of variation**	
□ a) Introduction of the change requires no further supportive data	□ IA_{IN}	□ IB*
□ b) Introduction of the change requires further supportive data	IB	
□ c) Introduction of a change for a biological/immunological medicinal product	IB	
□ x) Other variations	□ IA □ IB □ II	

* If one of the conditions is not met and the change is not listed as Type II.

B.II.h. Adventitious agents safety	
B.II.h.1. Update to the "Adventitious agents safety evaluation" information (section 3.2.A.2)	**Type of variation**
□ a) Manufacturing steps investigated for the first time for one or more adventitious agents	II
□ b) Replacement of obsolete studies related to manufacturing steps and adventitious agents already reported in the dossier	
1) with modification of risk assessment	II
2) without modification of risk assessment	IB

B.III. CERTIFICATE OF SUITABILITY /TSE CERTIFICATE OF SUITABILITY TO THE EUROPEAN PHARMACOPEIA/MONOGRAPH	
B.III.1. Submission of a new or updated certificate of suitability or deletion of certificate of suitability to the European Pharmacopeia: **For an API;** **For a starting material/reagent/intermediate used in the**	**Type of variation**

manufacturing process of the API; **For an excipient**		
a) Certificate of Suitability to the European Pharmacopoeia		
□ 1. New certificate from an already approved manufacturer	□ IA_{IN}	□ IB*
□ 2. Updated certificate from an already approved manufacturer	□ IA	□ IB*
□ 3. New certificate from a new manufacturer (replacement or addition)	□ IA_{IN}	□ IB*
□ 4. Deletion of certificates (in case multiple certificates exist per material)	□ IA	□ IB*
□ 5. New certificate for a non-sterile API that is to be used in a sterile medicinal product, where water is used in the last steps of the synthesis and the material is not claimed to be bacterial endotoxin free	IB	
b) European Pharmacopoeial TSE Certificate of suitability for an API/starting material/reagent/ intermediate/or excipient		
□ 1. New certificate for an API from a new or an already approved manufacturer	□ IA_{IN}	□ IB*
□ 2. New certificate for a starting material/reagent/ intermediate/or excipient from a new or an already approved manufacturer	□ IA	□ IB*
□ 3. Updated certificate from an already approved manufacturer	□ IA	□ IB*
□ 4. Deletion of certificates (in case multiple certificates exist per material)	□ IA	□ IB*
□ 5. New/updated certificate from an already-approved/new manufacturer using materials of human or animal origin for which an assessment of the risk with respect to potential contamination with adventitious agents is required	II	
□ x) Other variations	□ IA □ IB □ II	

* If one of the conditions is not met and the change is not listed as Type II.

B.III.2. Change to comply with the SPhU or Ph. Eur. Monograph or with a national pharmacopoeia of an EU state	**Type of variation**	
a) Change of specification(s) of a non-pharmacopoeial API to comply with the SPhU or Ph. Eur. monograph or with a national pharmacopoeia of an EU state		
□ 1. API	□ IA_{IN}	□ IB*
□ 2. Excipient/API starting material	□ IA	□ IB*
□ b) Change in specifications to comply with an update of the SPhU or European Pharmacopoeia or with a national pharmacopoeia of an	□ IA	□ IB*

EU state		
□ c) Change in specifications from requirements of the relevant monograph of the SPhU or national pharmacopoeia of an EU state to requirements of the Ph. Eur. monograph	□ IA	□ IB*
□ x) Other variations	□ IA □ IB □ II	

* If one of the conditions is not met and the change is not listed as Type II.

B.IV. MEDICAL DEVICES	**Type of variation**
□ x) Other variations	□ IA □ IB □ II

B.IV.1. Change of a device for dose measuring or administration of the medicinal product	**Type of variation**	
a) Addition or replacement of a device which is not an integrated part of the primary packaging		
□ 1. Device with CE marking	□ IA_{IN}	□ IB
□ 2. Spacer device for metered dose inhalers or other device which may have a significant impact on the delivery of the API in the dosage form (e.g. nebuliser)	II	
□ b) Deletion of a device	□ IA_{IN}	□ IB
□ c) Addition or replacement of a device which is an integrated part of the primary packaging	II	

* If one of the conditions is not met and the change is not listed as Type II.

B.V. CHANGES TO REGISTRATION CERTIFICATE AS A RESULT OF OTHER REGULATORY PROCEDURES		
B.V.a) PMF/VAMF (Plasma master file /Vaccine antigen master file		
B.V.a.1. Inclusion of a new, updated or amended Plasma Master File in the registration dossier of a medicinal product (PMF 2nd step procedure)	**Type of variation**	
□ a) First-time inclusion of a new Plasma Master File affecting the properties of the finished medicinal product	II	
□ b) First-time inclusion of a new Plasma Master File not affecting the properties of the finished medicinal product	IB	
□ c) Inclusion of an updated/amended Plasma Master File when changes affect the properties of the finished medicinal product	IB	
□ d) Inclusion of an updated/amended Plasma Master File when changes do not affect the properties of the finished medicinal product	□ IA_{IN}	□ IB*

* If one of the conditions is not met and the change is not listed as Type II.

B.V.a.2. Inclusion of a new, updated or amended Vaccine Antigen Master File in the registration dossier of a finished medicinal product (VAMF 2nd step procedure)	**Type of variation**	
□ a) First-time inclusion of a new Vaccine Antigen Master File	II	
□ b) Inclusion of an updated/amended Vaccine Antigen Master File, when changes affect the properties of the finished medicinal product	IB	
□ c) Inclusion of an updated/amended Vaccine Antigen Master File, when changes do not affect the properties of the finished medicinal product	□ IA_{IN}	□ IB*

* If one of the conditions is not met and the change is not listed as Type II.

C. SAFETY, EFFICACY, PHARMACOVIGILANCE CHANGES	**Type of variation**
□ x) Other variations	□ IA □ IB □ II

C.I.1. Change(s) in the summary of product characteristics, labelling text or instructions for medical use of a medicinal product authorized in EU according to a referral procedure	**Type of variation**	
□ a) The medicinal product is covered by the defined scope of the referral procedure	□ IA_{IN}	□ IB*
□ b) The medicinal product is not covered by the defined scope of the referral procedure but the change(s) implements the outcome of the procedure and no new additional data is required to be submitted by the marketing authorization holder	IB	
□ c) The medicinal product is not covered by the defined scope of the referral procedure but the change(s) implements the outcome of the procedure with new additional data submitted by the marketing authorization holder	II	

* If one of the conditions is not met and the change is not listed as Type II.

C.I.2. Change(s) in the summary of product characteristics, labelling text or instructions for medical use of a generic/hybrid/biosimilar medicinal products following introduction of the same change for the reference product	**Type of variation**
□ a) Change for which no new additional data is required	IB
□ b) Change(s) which require to be further substantiated by new additional data (e.g. comparability of biological medicinal products)	II

C.I.3. Change(s) in the summary of product characteristics, labelling text or instructions for medical use based on the periodic safety update report for the medicinal product or postregistration safety study, or the outcome of the assessment of the study report in compliance with the pediatric investigation plan (PIP)	**Type of variation**	
□ a) Change agreed by the competent authority	□ IA_{IN}	□ IB*
□ b) Change which require to be further substantiated by new additional data	II	
□ x) Other variations	□ IA □ IB □ II	

* If one of the conditions is not met and the change is not listed as Type II.

	Type of variation
□ **C.I.4. Changes in the summary of product characteristics, labelling text or instructions for medical use due to new quality, preclinical, clinical or pharmacovigilance data**	II

C.I.5. Change in the legal status of a medicinal product	**Type of variation**
□ a) For generic/hybrid/biosimilar medicinal products following an approved legal status change of the reference medicinal product	IB
□ b) All other legal status changes	II

C.I.6. Changes to therapeutic indications	**Type of variation**
□ a) Addition of a new therapeutic indication or modification of an approved one	II
□ b) Deletion of a therapeutic indication	IB

C.I.7. Deletion	**Type of variation**
□ a) a pharmaceutical form	IB
□ b) a strength	IB

C.I.8. Introduction of, or changes to, a summary of pharmacovigilance system	**Type of variation**

□ a) Introduction of a summary of pharmacovigilance system, changes in qualified person responsible for pharmacovigilance; the applicant's contact person for pharmacovigilance in Ukraine if not the same as the qualified person responsible for pharmacovigilance (including contact details) and/or changes in the Pharmacovigilance System Master File (PSMF) location	□ IA_{IN}	□ IB*

* If one of the conditions is not met and the change is not listed as Type II.

C.I.9. Change(s) to an existing pharmacovigilance system as described in the detailed description of the pharmacovigilance system (DDPS)	**Type of variation**	
□ a) Change in qualified person responsible for pharmacovigilance and/or the applicant's contact person for pharmacovigilance in Ukraine if not the same as the qualified person responsible for pharmacovigilance, and/or contact details and/or and/or back-up procedure	□ IA_{IN}	□ IB*
□ b) Change(s) in the safety database and/or major contractual arrangements for the fulfilment of pharmacovigilance obligations, and /or change of the site undergoing pharmacovigilance activities	□ IA_{IN}	□ IB*
□ c) Other change(s) to the detailed description of the pharmacovigilance system that does not impact on the operation of the pharmacovigilance system (e.g. change of the major storage/archiving location, administrative changes)	□ IA	□ IB*
□ d) Change(s) to a detailed description of the pharmacovigilance system following the assessment of the same DDPS in relation to another medicinal product of the same registration certificate holder	□ IA_{IN}	□ IB*
□ x) Other variations	□ IA □ IB □ II	

* If one of the conditions is not met and the change is not listed as Type II.

	Type of variation	
□ C**.1.10. Change in the frequency and/or date of submission of periodic safety update reports (PSUR) for medicinal products**	□ IA_{IN}	□ IB*

* If one of the conditions is not met and the change is not listed as Type II.

C.1.11. Introduction of, or change(s) to, the obligations and conditions of issuing registration certificate, including the risk management plan	**Type of variation**	
□ a) Implementation of wording agreed by the competent authority	□ IA_{IN}	□ IB*

□ b) Implementation of change(s) which require to be further substantiated by new additional data to be submitted to the competent authority where significant assessment by the competent authority is required	II
□ x) Other variations	□ IA □ IB □ II

* If one of the conditions is not met and the change is not listed as Type II.

	Type of variation	
□ **C.1.12. Inclusion or deletion of black symbol and explanatory statements for medicinal products in the list of medicinal products that are subject to additional monitoring**	□ IA_{IN}	□ IB*

* If one of the conditions is not met and the change is not listed as Type II.

	Type of variation
□ **C.1.13. Other variations not covered in this section which involve the submission of study results to the competent authority**	II

D. PMF/VAMF (Plasma master file /Vaccine antigen master file)	**Type of variation**
□ x) Other variations	□ IA □ IB □ II

	Type of variation	
□ **D.1. Change in the name and/or address of the VAMF holder**	□ IA_{IN}	□ IB*

* If one of the conditions is not met and the change is not listed as Type II.

	Type of variation	
□ **D.2. Change in the name and/or address of the PMF holder**	□ IA_{IN}	□ IB*

* If one of the conditions is not met and the change is not listed as Type II.

	Type of variation	
□ **D.3. Change or transfer of the approved PMF holder to a new PMF holder (i.e. different legal entity)**	□ IA_{IN}	□ IB*

* If one of the conditions is not met and the change is not listed as Type II.

	Type of variation	
□ D.4. Change in the name and/or address of a blood establishment including blood/plasma collection centers	□ IA	□ IB*

* If one of the conditions is not met and the change is not listed as Type II.

	Type of variation
□ D.5. Replacement or addition of a blood/plasma collection center within those included in the PMF	IB

	Type of variation	
□ D.6. Deletion or change of status (operational/non-operational) of establishment(s)/center(s) used for blood/plasma collection or in the testing of blood donations and plasma pools	□ IA	□ IB

* If one of the conditions is not met and the change is not listed as Type II.

	Type of variation
□ D.7. Addition of a new establishment for the collection of blood not included in the PMF	II

	Type of variation
□ D.8. Replacement or addition of a blood center for testing of blood donations and/or plasma pools within an establishment included in the PMF	IB

	Type of variation
□ D.9. Addition of a new blood establishment for testing of blood donations and/or plasma pool not included in the PMF	II

	Type of variation
□ D.10. Replacement or addition of a new blood establishment or center(s) in which storage of plasma is carried out	IB

	Type of variation	
□ D.11. Deletion of a blood establishment or center(s) in which storage of plasma is carried out	□ IA	□ IB*

* If one of the conditions is not met and the change is not listed as Type II.

	Type of variation
□ **D.12. Replacement or addition of an organisation involved in the transport of plasma**	IB

	Type of variation	
□ **D.13. Deletion of an organisation involved in the transport of plasma**	□ IA	□ IB*

* If one of the conditions is not met and the change is not listed as Type II.

	Type of variation	
□ **D.14. Addition of a CE-marked test kit to test individual blood donations as a new test kit or as a replacement of one included in the PMF**	□ IA	□ IB*

* If one of the conditions is not met and the change is not listed as Type II.

D.15. Addition of a non-CE marked test kit to test individual blood donations as a new test kit or as a replacement of one included in the PMF	**Type of variation**	
□ a) The new test kit has not previously been approved in the PMF for any blood center for testing of blood donations	II	
□ b) The new test kit has been approved in the PMF for other blood center(s) for testing of blood donations	□ IA	□ IB*

* If one of the conditions is not met and the change is not listed as Type II.

	Type of variation
□ **D.16. Change of kit/method used to test plasma pools (antibody or antigen or NAT test (nucleic acid amplification technology))**	II

	Type of variation	
□ **D.17. Introduction or extension of blood donation inventory hold period**	□ IA	□ IB*

* If one of the conditions is not met and the change is not listed as Type II.

	Type of variation
□ **D.18. Removal of blood donation inventory hold period or reduction in its length**	IB

D.19. Replacement or addition of blood containers (e.g. bags, bottles)	**Type of variation**	
□ a) The new blood containers are CE-marked	□ IA	□ IB*
□ b) The new blood containers are not CE-marked	II	

* If one of the conditions is not met and the change is not listed as Type II.

D.20. Change in storage/transport	**Type of variation**	
□ a) Storage and/or transport conditions	□ IA	□ IB*
□ b) Maximum storage time for the plasma	□ IA	□ IB*

* If one of the conditions is not met and the change is not listed as Type II.

	Type of variation
□ **D.21. Introduction of test for viral markers when this introduction will have significant impact on the viral risk assessment**	II

	Type of variation
□ **D.22. Change in the plasma pool preparation (e.g. manufacturing method, pool size, storage of plasma pool samples)**	IB

	Type of variation
□ **D.23. Change in the steps that would be taken if it is found retrospectively that blood donation(s) should have been excluded from processing (retrospective studies)**	II

Changes to module 1 of the registration dossier	o	Overview	o
Changes to module 2 of the registration dossier	o	Summary	o

Changes to module 3 of the registration dossier	o	Updating	o
Changes to module 4 of the registration dossier	o	Addition	o
Changes to module 5 of the registration dossier	o		

Other changes (changes shall be listed in brief)

Changes for which this registration form is submitted:

Content of proposed changes (changes shall be listed in brief)

Exact scope, justification of proposed changes and classification of unforeseen changes (if any) (including description and conditions for all proposed changes. If a change relates to unforeseen changes a justification of its propsed classification shall be included)

Current wording*	Proposed wording*

Add (if necessary) the revised summary of product characteristics, instructions for medical use, labelling text and other materials which justify introduction of changes.

{Annex 26 in wording of MoH Ukraine Order №460 as of 23.07.2015}